PSC
Patient Square Capital Portfolio holdings
AUM
$277M
This Quarter Return
+15.38%
1 Year Return
+6.76%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$277M
AUM Growth
+$277M
(+15%)
Cap. Flow
+$4.8M
Cap. Flow
% of AUM
1.73%
Top 10 Holdings %
Top 10 Hldgs %
90%
Holding
22
New
3
Increased
3
Reduced
10
Closed
3
Top Buys
| 1 |
argenx
ARGX
|
$16M |
| 2 |
Insmed
INSM
|
$2.87M |
| 3 |
Geron
GERN
|
$1.01M |
| 4 |
Cidara Therapeutics
CDTX
|
$731K |
| 5 |
Allogene Therapeutics
ALLO
|
$302K |
Top Sells
| 1 |
Liquidia Corp
LQDA
|
$6.26M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$3.41M |
| 3 |
Intellia Therapeutics
NTLA
|
$1.66M |
| 4 |
Soleno Therapeutics
SLNO
|
$1.33M |
| 5 |
EyePoint Pharmaceuticals
EYPT
|
$1.22M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.15B
| $141M | 50.71% | 12,480,000 | – | – |
|
|
2
Insmed
INSM
$28.8B
| $36.1M | 13.02% | 358,800 +28,550 | +9% | +$2.87M |
|
|
3
argenx
ARGX
$43.6B
| $16M | 5.76% | +29,000 | New | +$16M |
|
|
4
EyePoint Pharmaceuticals
EYPT
$797M
| $12.7M | 4.59% | 1,352,837 -129,140 | -9% | -$1.22M |
|
|
5
Liquidia Corp
LQDA
$2.38B
| $12.7M | 4.58% | 1,020,000 -502,452 | -33% | -$6.26M |
|
6
Ocular Therapeutix
OCUL
$2.12B
| $7.59M | 2.74% | 817,699 -102,500 | -11% | -$951K |
|
7
Cullinan Oncology
CGEM
$445M
| $6.54M | 2.36% | 868,897 -10,000 | -1% | -$75.3K |
|
8
Kymera Therapeutics
KYMR
$2.95B
| $6.11M | 2.2% | 140,000 -2,201 | -2% | -$96.1K |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $5.77M | 2.08% | 113,462 -2,900 | -2% | -$148K |
|
10
Scholar Rock
SRRK
$3.14B
| $5.45M | 1.97% | 154,000 | – | – |
|
11
Enliven Therapeutics
ELVN
$1.2B
| $4.93M | 1.78% | 245,838 -8,000 | -3% | -$160K |
|
12
Nurix Therapeutics
NRIX
$714M
| $4.7M | 1.69% | 412,296 -35,000 | -8% | -$399K |
|
13
Agios Pharmaceuticals
AGIO
$2.19B
| $4.65M | 1.68% | 139,732 | – | – |
|
14
Pharvaris
PHVS
$1.39B
| $4.3M | 1.55% | 244,283 -1,213 | -0.5% | -$21.3K |
|
15
Disc Medicine
IRON
$2.07B
| $3.92M | 1.41% | 74,000 -9,000 | -11% | -$477K |
|
|
16
Allogene Therapeutics
ALLO
$251M
| $2.98M | 1.07% | 2,635,000 +266,814 | +11% | +$302K |
|
|
17
Geron
GERN
$893M
| $1.01M | 0.36% | +716,000 | New | +$1.01M |
|
|
18
Cidara Therapeutics
CDTX
$1.66B
| $731K | 0.26% | +15,000 | New | +$731K |
|
19
VYNE Therapeutics
VYNE
$8.16M
| $523K | 0.19% | 317,033 +60,000 | +23% | +$99K |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| – | – | -38,500 | Closed | -$3.41M |
|
|
21
Intellia Therapeutics
NTLA
$1.22B
| – | – | -232,781 | Closed | -$1.66M |
|
|
22
Soleno Therapeutics
SLNO
$3.6B
| – | – | -18,600 | Closed | -$1.33M |
|